5 years safety of fingolimod in real world: First results from PANGAEA, a non-interventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice (P5.365)

Conclusions:The results of the 5 year interim analysis of PANGAEA support the positive benefit-risk profile fingolimod demonstrated in phase III clinical trials with real world evidence data. The frequency/nature of reported adverse events is consistent with previous findings from clinical trials.Study Supported by: This study was supported by the Novartis Pharma GmbH, Nuremberg, Germany.Disclosure: Dr. Ziemssen has received personal compensation for activities with Dr. Albrecht has received personal compensation for activities with Sanofi Genzyme, Novartis, and Biogen. Dr. Haas has received personal compensation for activities with Bayer Schering, Teva Aventis, Merck Serono, Biogen Idec, Allergan, Inc., and Octapharma as a consultant. Dr. Klotz has received personal compensation for activities with Genzyme, Novartis, CSL Behring, and Merck Serono as an advisory board member and a speaker. Dr. Lang has received personal compensation for activities with Novartis, Biogen Idec, Bayer, Teva, Serono and Genzyme. Dr. Lassek has received personal compensation for activities with Teva, Merck Serono, Genzyme -Sanofi, Novartis, Bayer, and Biogen. Dr. Schmidt received personal compensation for activities with Bayer Vital, Biogen Idec, MerckSerono, Teva, Sanofi, and Novartis as a scientific advisory board member and a speaker. Dr. Tackenberg has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Merck Serono, Novartis Pharma, and Teva Pharma as a speaker an...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Ziemssen, T., Albrecht, H., Haas, J., Klotz, L., Lang, M., Lassek, C., Schmidt, S., Tackenberg, B., Cornelissen, C. Tags: Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes II Source Type: research